desferrioxamine-b-succinyl-phenylalanine(1)-octreotide and Carcinoma--Islet-Cell

desferrioxamine-b-succinyl-phenylalanine(1)-octreotide has been researched along with Carcinoma--Islet-Cell* in 1 studies

Other Studies

1 other study(ies) available for desferrioxamine-b-succinyl-phenylalanine(1)-octreotide and Carcinoma--Islet-Cell

Article	Year
Gallium-67/gallium-68-[DFO]-octreotide--a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radiolabeling in vitro and preliminary in vivo studies. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1994, Volume: 35, Issue:2 When labeled with gamma-emitting radionuclides, somatostatin analogs have the potential to localize somatostatin receptor-positive tumors using gamma camera scintigraphy. We present a somatostatin analog, [DFO]-octreotide (SDZ 216-927), that comprises desferrioxamine B coupled to octreotide via a succinyl linker. This conjugate can be labeled with either 67Ga for gamma scintigraphy or 68Ga for PET imaging. The 67Ga-labeled conjugate is stable in vitro to autoradiolysis over a 24-hr period.. Rats bearing a somatostatin receptor-positive pancreatic islet cell tumor were injected with 20 MBq of 67Ga[DFO]-octreotide (33 GBq 67Ga/mumole).. After 1 hr, the accumulation of 67Ga[DFO]-octreotide was 0.38 +/- 0.08 %ID/g and the tumor-to-nontumor ratios for blood, muscle, liver and intestine were 2.5, 7.4, 1.9 and 1.6, respectively. PET studies with 68Ga[DFO]-octreotide recorded a very rapid accumulation at the tumor and a subsequent residence half-life of about 6 hr.. Gallium-68-[DFO]-octreotide can be used in PET studies to diagnose receptor-positive tumors such as gastroenteropancreatic, small-cell lung and breast tumors. Topics: Animals; Carcinoma, Islet Cell; Deferoxamine; Humans; In Vitro Techniques; Isotope Labeling; Octreotide; Pancreatic Neoplasms; Rats; Receptors, Somatostatin; Tissue Distribution; Tomography, Emission-Computed	1994

Article

Year

Gallium-67/gallium-68-[DFO]-octreotide--a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radiolabeling in vitro and preliminary in vivo studies.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1994, Volume: 35, Issue:2

When labeled with gamma-emitting radionuclides, somatostatin analogs have the potential to localize somatostatin receptor-positive tumors using gamma camera scintigraphy. We present a somatostatin analog, [DFO]-octreotide (SDZ 216-927), that comprises desferrioxamine B coupled to octreotide via a succinyl linker. This conjugate can be labeled with either 67Ga for gamma scintigraphy or 68Ga for PET imaging. The 67Ga-labeled conjugate is stable in vitro to autoradiolysis over a 24-hr period.. Rats bearing a somatostatin receptor-positive pancreatic islet cell tumor were injected with 20 MBq of 67Ga[DFO]-octreotide (33 GBq 67Ga/mumole).. After 1 hr, the accumulation of 67Ga[DFO]-octreotide was 0.38 +/- 0.08 %ID/g and the tumor-to-nontumor ratios for blood, muscle, liver and intestine were 2.5, 7.4, 1.9 and 1.6, respectively. PET studies with 68Ga[DFO]-octreotide recorded a very rapid accumulation at the tumor and a subsequent residence half-life of about 6 hr.. Gallium-68-[DFO]-octreotide can be used in PET studies to diagnose receptor-positive tumors such as gastroenteropancreatic, small-cell lung and breast tumors.

Topics: Animals; Carcinoma, Islet Cell; Deferoxamine; Humans; In Vitro Techniques; Isotope Labeling; Octreotide; Pancreatic Neoplasms; Rats; Receptors, Somatostatin; Tissue Distribution; Tomography, Emission-Computed

1994